Business Standard

Trust DCGI to ask for enough data before vaccine approval: Gagandeep Kang

Having achieved the first goal of seeing whether the vaccines work, we can be more ambitious and design studies to assess whether and how much they reduce transmission, says Kang

Gagandeep Kang
Premium

Theoretically, anywhere from 50 per cent to 80 per cent of people may need to be inoculated to stop the virus spread, says Kang. Image: CMC

Akash Podishetty Hyderabad
Even as leading pharmaceutical companies are seeking authorisation to roll out their coronavirus vaccines in India, the regulator should not give its approval without first obtaining enough data, suggests Gagandeep Kang, a professor at the Wellcome Trust Research Laboratory of Christian Medical College, Vellore, and one of India's leading medical scientists. “Pfizer has done no trials in India, and Serum has not completed its immunogenicity study,” she says in an emailed interview with Akash Podishetty. Edited excerpts:

A Lancet study shows that the Oxford vaccine's ability to prevent transmission is limited. Even in Pfizer's case, we still don't know of

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in